Safar Partners
VC Fund
Cambridge, United States
Safar Partners is a seed- to growth-stage venture fund investing primarily in technology companies out of MIT, Harvard, and the University of Rochester. We invest in platform technologies in the cleantech and advanced materials, AI/IT and robotics, and life science/medical device areas.
- Total investments:
- 96
- Last investment:
- Lead investor:
- 20%
- Fund size:
- $12M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Safar Partners invests in
Stages Safar Partners invests in
Countries Safar Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $1.5M–$17M
- Series A
- $11M–$40M
- Series B
- $7M–$863M
Investment Focus
Industry
- Biotechnology 11 (11%)
- Health Care 9 (9%)
- Information Technology 9 (9%)
- Manufacturing 7 (7%)
- Artificial Intelligence 7 (7%)
Stage
- Seed 22 (23%)
- Series A 18 (19%)
- Series B 15 (16%)
- Venture - Series Unknown 12 (13%)
- Funding Round 5 (5%)
Country
- United States 56 (58%)
- China 1 (1%)
- Italy 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Arunas Chesonis
Managing Partner & Investment Committee Member
|
Managing Partner & Investment Committee Member | Total investments: 14 | Find email | |
Nader Motamedy
Founder & Managing Partner
|
Founder & Managing Partner | Total investments: 7 | Find email | |
Vera Schroeder
Associate
|
Associate | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $135M / Series B / Oct 13, 2026 | ||
| Blaze Energy Technologies is a manufacturing company that develops technologies to adopt alternative fuels through existing engines. | $6.5M / Seed / Oct 06, 2026 | ||
| Quintessent is a Santa Barbara start-up that commercializes quantum dot-based lasers and photonic integrated circuits. Its solutions leverage the unique properties of quantum dot gain media with co-designed architectures to enable future applications in optical networking, deep learning systems, and sensing.It is based in Santa Barbara,California. | $40M / Series A / Aug 24, 2026 | ||
| EELI Technology Inc., a Silicon Valley–based critical minerals technology company, enables lithium production from sources once considered impossible to mine economically —cheaper, faster, electrified. | $2M / Pre-Seed / Jul 21, 2026 | ||
| Quaise is an energy company that is developing and commercializing novel millimeter-wave drilling systems to harness geothermal energy around the globe, overcoming the geographic constraints limiting this energy source today. The company was founded in 2018 and is based in Cambridge, Massachusetts. | $134.1M / Series B / Jul 07, 2026 | ||
| Gradiant is a solutions provider and developer of cleantech water projects for advanced water and wastewater treatment. They provide microelectronics, pharmaceuticals, food and beverage, lithium and key minerals, and renewable energy. | Series E / May 18, 2026 | ||
| Via Separations is enabling industrial decarbonization with its novel chemistries that allow manufacturing facilities to slash their energy consumption while making more product. Targeting the 12% of US energy consumption that is wasted each year separating chemicals, Via reduces the load of the process by 90%, electrifies the mostenergy-intensive step in chemical production, and generates additional revenue for the customer. Today, Via is deploying its technology in pilot trials at pulp & paper facilities to eliminate 100 million metric tons of CO2 by 2050. Via’s innovation is a highly selective and robust membrane filter that replaces the energy-inefficient heat-based separations in industrial processes. Spun out of MIT’s Department of Material Science & Engineering, Via has scaled up the technology by more than 10 million times and demonstrated working prototypes at a commercial scale. | $36M / Venture - Series Unknown / Apr 01, 2026 | ||
| Gelmedix is a developer of a biomaterial platform to improve drug delivery for complicated ophthalmic treatment. The company's platform offers a single non-invasive gel patch that can be used as a drug-eluting sealant with tissue adhesion, tunable drug elution, and biocompatibility properties, thereby enabling healthcare providers to reducethe usage of drops which cause inconvenience to patients. | $13M / Seed / Feb 17, 2026 | ||
| Alva Energy specializes in nuclear plant upgrades called "uprates" to boost clean power output from existing U.S. reactors. It standardizes complex retrofits into repeatable, turnkey projects for faster and cheaper deployment. | $33M / Series A / Feb 12, 2026 | ||
| Zanskar develops a predictive platform informed by massive data for discovering previously unknown geothermal resources. Its platform includes subsurface characterization technology and massive data sets, enhancing and reducing risk in the exploration of geothermal resources. | $115M / Series C / Jan 21, 2026 | ||
| See all 96 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Safar Partners invest in?
Safar Partners invests primarily in Biotechnology, Health Care and Information Technology startups, most often at Seed and Series A stage. Most of the 96 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Safar Partners invest in?
Safar Partners typically joins rounds of $1.5M–$17M at Seed, $11M–$40M at Series A and $7M–$863M at Series B. These are whole funding-round sizes, not Safar Partners's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Safar Partners took part in.
How do I contact Safar Partners?
Public channels for Safar Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Safar Partners?
The team at Safar Partners includes Arunas Chesonis (Managing Partner & Investment Committee Member), Nader Motamedy (Founder & Managing Partner) and Vera Schroeder (Associate). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
